NO974811L - CNS growth modulators, preparations, cells and methods which include and utilize such - Google Patents
CNS growth modulators, preparations, cells and methods which include and utilize suchInfo
- Publication number
- NO974811L NO974811L NO974811A NO974811A NO974811L NO 974811 L NO974811 L NO 974811L NO 974811 A NO974811 A NO 974811A NO 974811 A NO974811 A NO 974811A NO 974811 L NO974811 L NO 974811L
- Authority
- NO
- Norway
- Prior art keywords
- nerve
- methods
- cells
- adhesion molecule
- molecules
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title 1
- 210000005036 nerve Anatomy 0.000 abstract 5
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- 238000011830 transgenic mouse model Methods 0.000 abstract 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- 102000006386 Myelin Proteins Human genes 0.000 abstract 1
- 108010083674 Myelin Proteins Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000001130 astrocyte Anatomy 0.000 abstract 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000005012 myelin Anatomy 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000002955 secretory cell Anatomy 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biodiversity & Conservation Biology (AREA)
Abstract
En fremgangsmåte for å fremme nervevekst ±n vivo i pattedyrsentral-nervesystemet ved administrering av et nervecelleadhesjonsmolekyl som kan overvinne inhibitoriske molekylære stikkord funnet på gliaceller og myelin for å fremme nervevekst. Aktive frag-menter, beslektede molekyler, molekyler av samme type, etterligninger, analoger, utskillende celler og opp-løselige molekyler derav, så vel som antistoffer mot disse, og DNA-molekyler, vektorer og transformerte celler som er i stand til å uttrykke disse er også beskrevet. Transgene muselinjer som uttrykker et nerveadhesjonsmolekyl i differensierte astrocytter og celler og vev avledet fra disse er også beskrevet. Ekspresjon av nerveadhesjonsmolekylet øker neurittutvekst på sentralnervesystemvev avledet fra disse transgene mus. Fremgangsmåter for å øke neuronutvekst fra CNS-neuroner, for-bedre hukommelsen ogkning av synaptisk effektivitet er også beskrevet. Fremgangsmåter for testing av legemidler som modulerer virkningen av nerveadhesjonsmolekylet og analyse-systemer egnede for slike metoder er også beskrevet.A method of promoting nerve growth ± n vivo in the mammalian central nervous system by administering a nerve cell adhesion molecule capable of overcoming inhibitory molecular keywords found on glial cells and myelin to promote nerve growth. Active fragments, related molecules, molecules of the same type, imitations, analogues, secretory cells and soluble molecules thereof, as well as antibodies against them, and DNA molecules, vectors and transformed cells capable of expressing them is also described. Transgenic mouse lines expressing a nerve adhesion molecule in differentiated astrocytes and cells and tissues derived therefrom are also described. Expression of the nerve adhesion molecule increases neurite outgrowth on central nervous system tissues derived from these transgenic mice. Methods for increasing neuronal growth from CNS neurons, enhancing memory and increasing synaptic efficiency have also been described. Methods for testing drugs that modulate the action of the nerve adhesion molecule and assay systems suitable for such methods are also described.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42499595A | 1995-04-19 | 1995-04-19 | |
| US48395995A | 1995-06-07 | 1995-06-07 | |
| PCT/US1996/005434 WO1996032959A1 (en) | 1995-04-19 | 1996-04-19 | Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO974811D0 NO974811D0 (en) | 1997-10-17 |
| NO974811L true NO974811L (en) | 1997-12-19 |
Family
ID=27026535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO974811A NO974811L (en) | 1995-04-19 | 1997-10-17 | CNS growth modulators, preparations, cells and methods which include and utilize such |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0821591A1 (en) |
| JP (1) | JPH11504211A (en) |
| KR (1) | KR19990007893A (en) |
| AU (1) | AU718508B2 (en) |
| CA (1) | CA2218599A1 (en) |
| CZ (1) | CZ330197A3 (en) |
| EA (1) | EA199700323A1 (en) |
| HU (1) | HUP9900060A3 (en) |
| IS (1) | IS4590A (en) |
| MX (1) | MX9708127A (en) |
| NO (1) | NO974811L (en) |
| PL (1) | PL322947A1 (en) |
| SK (1) | SK142497A3 (en) |
| TR (2) | TR199701203T1 (en) |
| WO (1) | WO1996032959A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2190418A1 (en) * | 1996-11-15 | 1998-05-15 | Zhi-Cheng Xiao | Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof |
| WO1998036062A1 (en) * | 1997-02-13 | 1998-08-20 | Smithkline Beecham Plc | Neural cell adhesion molecule splicing variants |
| CA2343975A1 (en) * | 1998-09-29 | 2000-04-06 | Lars Christian Ronn | Ncam binding compounds |
| AUPQ614200A0 (en) * | 2000-03-10 | 2000-03-30 | Department Of Human Physiology, Flinders University School Of Medicine | Method for treating chronic spinal cord injury |
| AU2001249835A1 (en) * | 2000-04-03 | 2001-10-15 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of alzheimer's disease |
| JP2003284574A (en) * | 2001-10-03 | 2003-10-07 | Pfizer Prod Inc | Nucleic acid molecules, polypeptides, and uses thereof including diagnosis and treatment of Alzheimer's disease |
| TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| GB0306309D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
| ES2704030T3 (en) * | 2009-08-07 | 2019-03-13 | Affinimark Tech Inc | Methods for the immunological identification of cerebrospinal fluid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005191A1 (en) * | 1988-11-04 | 1990-05-17 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
| AU2152092A (en) * | 1991-06-24 | 1993-01-25 | Erziehungsdirektion Of The Canton Zurich | Neurite growth regulatory factors |
| AU1091495A (en) * | 1993-11-08 | 1995-05-29 | New York University | Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage |
-
1996
- 1996-04-19 EP EP96912910A patent/EP0821591A1/en not_active Withdrawn
- 1996-04-19 SK SK1424-97A patent/SK142497A3/en unknown
- 1996-04-19 CZ CZ973301A patent/CZ330197A3/en unknown
- 1996-04-19 TR TR97/01203T patent/TR199701203T1/en unknown
- 1996-04-19 WO PCT/US1996/005434 patent/WO1996032959A1/en not_active Ceased
- 1996-04-19 TR TR1998/01650T patent/TR199801650T2/en unknown
- 1996-04-19 JP JP8531932A patent/JPH11504211A/en active Pending
- 1996-04-19 KR KR1019970707416A patent/KR19990007893A/en not_active Withdrawn
- 1996-04-19 PL PL96322947A patent/PL322947A1/en unknown
- 1996-04-19 HU HU9900060A patent/HUP9900060A3/en unknown
- 1996-04-19 CA CA002218599A patent/CA2218599A1/en not_active Abandoned
- 1996-04-19 AU AU55572/96A patent/AU718508B2/en not_active Ceased
- 1996-04-19 EA EA199700323A patent/EA199700323A1/en unknown
-
1997
- 1997-10-15 IS IS4590A patent/IS4590A/en unknown
- 1997-10-17 NO NO974811A patent/NO974811L/en not_active Application Discontinuation
- 1997-10-20 MX MX9708127A patent/MX9708127A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR199701203T1 (en) | 1998-03-21 |
| MX9708127A (en) | 1998-06-28 |
| AU718508B2 (en) | 2000-04-13 |
| EP0821591A1 (en) | 1998-02-04 |
| CZ330197A3 (en) | 1998-04-15 |
| CA2218599A1 (en) | 1996-10-24 |
| AU5557296A (en) | 1996-11-07 |
| KR19990007893A (en) | 1999-01-25 |
| JPH11504211A (en) | 1999-04-20 |
| PL322947A1 (en) | 1998-03-02 |
| NO974811D0 (en) | 1997-10-17 |
| EA199700323A1 (en) | 1998-04-30 |
| HUP9900060A3 (en) | 2001-08-28 |
| HUP9900060A2 (en) | 1999-04-28 |
| WO1996032959A1 (en) | 1996-10-24 |
| TR199801650T2 (en) | 1999-03-22 |
| SK142497A3 (en) | 1999-08-06 |
| IS4590A (en) | 1997-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schmid | The mechanism of receptor‐mediated endocytosis: More questions than answers | |
| Simova et al. | Carbohydrate mimics promote functional recovery after peripheral nerve repair | |
| NO974811L (en) | CNS growth modulators, preparations, cells and methods which include and utilize such | |
| Hartmann et al. | Formation of specific amino acid sequences during thermal polymerization of amino acids | |
| DE69634043D1 (en) | CIRCULAR DNA MOLECULAR WITH A DEPENDENT REACTION TREATMENT, ITS MANUFACTURING PROCESS AND ITS USE IN GENETHERAPY | |
| Willard et al. | Molecular events in axonal regeneration | |
| ATE348175T1 (en) | METHOD OF INTRACELLULAR BINDING OF TARGETED MOLECULES | |
| AU5320196A (en) | The gc1q receptor, hiv-1 gp120 region binding thereto, and r elated peptides and targeting antibodies | |
| WO1999009057A3 (en) | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns | |
| Trevor et al. | Acetylcholinesterases | |
| ZA963971B (en) | A method and nucleotide sequence for transforming microorganisms | |
| Gibbons et al. | A method for the separation of hybrids of chromatographically identical oligomeric proteins. Use of 3, 4, 5, 6-tetrahydrophthaloyl groups as a reversible" chromatographic handle" | |
| Bisby | Retrograde axonal transport and nerve regeneration | |
| Berski et al. | Synthesis and biological evaluation of a polysialic acid-based hydrogel as enzymatically degradable scaffold material for tissue engineering | |
| Arshavsky et al. | Control of feeding movements in the freshwater snail Planorbis corneus: II. Activity of isolated neurons of buccal ganglia | |
| Fox | Thermal proteins in the first life and in the “mind-body” problem | |
| Grafstein et al. | Role of fast axonal transport in regeneration of goldfish optic axons | |
| Roubos et al. | Adenylate cyclase activity in axon terminals of ovulation-hormone producing neuroendocrine cells of Lymnaea stagnalis (L.) | |
| Brossmer et al. | Chemical modification of human chorionic gonadotropin and its biological and immunological characterization | |
| DE69631624D1 (en) | ANTIBODIES AGAINST HUMAN RESTRICTIN | |
| Ichikawa et al. | The difference of osteocalcin-immunoreactive neurons in the rat dorsal root and trigeminal ganglia: co-expression with nociceptive transducers and central projection | |
| BAXTER et al. | L16, a bifunctional ribosomal protein and the enhancing effect of L6 and L11 | |
| Du Moulin et al. | Effect of some phosphodiesterase inhibitors on two different preparations of adenosine 3′, 5′-monophosphate phosphodiesterase | |
| Wolters | On the anatomy of descending pathways from the brain stem to the spinal cord in a lizard, Varanus exanthematicus | |
| Sheikh | Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |